Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions.
New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of opioid dependence and chronic pain, rare diseases, oncology and supportive care, which are developed in-house and in collaboration with international pharmaceutical companies.
1991
HeadquartersIdeongatan 1A, 22362 Lund – Sweden
55,383,447
IPOJan. 1, 2000
Stock exchange(s)Nasdaq Stockholm